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Abstract
Background: Adrenomedullin and endothelin-1 are hormones with opposing effects on the cardiovascular system.
Adrenomedullin acts as a vasodilator and seems to be important for the initiation and continuation of the hyperdynamic
circulatory response in sepsis. Endothelin-1 is a vasoconstrictor and has been linked to decreased cardiac performance.
Few studies have studied the relationship between adrenomedullin and endothelin-1, and morbidity and mortality in
septic shock patients. High-sensitivity troponin T (hsTNT) is normally used to diagnose acute cardiac injury but is also
prognostic for outcome in intensive care. We investigated the relationship between mid-regional pro-adrenomedullin
(MR-proADM), C-terminal pro-endothelin-1 (CT-proET-1), and myocardial injury, measured using transthoracic
echocardiography and hsTNT in septic shock patients. We were also interested in the development of different
biomarkers throughout the ICU stay, and how early measurements were related to mortality. Further, we assessed
if a positive biomarker panel, consisting of MR-proADM, CT-proET-1, and hsTNT changed the odds for mortality.
Methods: A cohort of 53 consecutive patients with septic shock had their levels of MR-proADM, CT-proET-1,
hsTNT, and left ventricular systolic functions prospectively measured over 7 days. The relationship between day 1
levels of MR-proADM/CT-proET-1 and myocardial injury was studied. We also investigated the relationship between
biomarkers and early (7-day) and later (28-day) mortality. Likelihood ratios, and pretest and posttest odds for mortality
were calculated.
Results: Levels of MR-proADM and CT-proET-1 were significantly higher among patients with myocardial injury and
were correlated with left ventricular systolic dysfunction. MR-proADM and hsTNT were significantly higher among
7-day and 28-day non-survivors. CT-proET-1 was also significantly higher among 28-day but not 7-day non-survivors.
A positive biomarker panel consisting of the three biomarkers increased the odds for mortality 13-fold to 20-fold.
Conclusions: MR-proADM and CT-proET-1 are associated with myocardial injury. A biomarker panel combining
MR-proADM, CT-proET-1, and hsTNT increases the odds ratio for death, and may improve currently available scoring
systems in critical care.
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Background
Circulatory failure is one of the most severe manifesta-
tions of early sepsis. Whilst numerous studies have in-
vestigated novel biomarkers to diagnose and risk-stratify
patients with sepsis, none have become universally ac-
cepted and few have focused on the circulatory system
per se. As septic shock still accounts for an unacceptable
number of deaths in the critically ill, we reasoned that a
biomarker strategy using a combination of clinical, bio-
chemical, and physiological parameters focusing on the
circulatory system may be one way of stratifying very high-
risk patients.
Endothelial activation is a hallmark of sepsis and thought
to play a key role in the pathophysiology of septic
shock. In this regard, three novel biomarkers have been
described that may have contributory and/or predictive
roles in the development of circulatory failure – mid-
regional pro-adrenomedullin (MR-proADM), C-terminal
pro-endothelin-1 (CT-proET-1), and high-sensitivity tropo-
nin T (hsTNT).
Adrenomedullin (ADM) is a 52-amino acid peptide
hormone, which is associated with cardiovascular, en-
docrine, and renal mechanisms that control fluid and
electrolyte homeostasis [1]. ADM acts as a vasodilator,
decreases peripheral vascular resistance, and increases
cardiac output [2, 3]. ADM also decreases capillary
hyperpermeability during septic shock [4, 5]. Because of
the instability of the peptide, it has been shown that
measurements of the mid-regional portion of the pre-
cursor peptide pro-adrenomedullin, is more suitable for
clinical practice [6]. Few clinical studies have described
ADM in septic shock. In the largest study to date,
Guignant et al. [7] showed that increased plasma MR-
proADM was associated with 28-day mortality.
Endothelin-1 (ET-1) is a 21-amino acid peptide, which
acts as a potent vasoconstrictor and has mitogenic ef-
fects on smooth muscle cells. ET-1 has been shown to
be involved in multiple physiological functions related to
the nervous, renal, cardiovascular, respiratory, gastrointes-
tinal, and endocrine systems [8]. Because of its short half-
life (1–7 minutes) [8, 9], and almost total clearance from
the blood stream by pulmonary passage, CT-proET-1 has
been found to stoichiometrically measure ET-1 [9].
Cardiac troponin (cTn) is the preferred marker of myo-
cardial ischemia and injury [10]. New high-sensitivity tropo-
nin assays have, by detecting extremely low levels, been
associated with conditions other than myocardial infarc-
tion and predict worse outcome in intensive care [10–16].
As both ADM and ET-1 are potent vasoactive factors it is
also plausible that they may be associated with myocardial
dysfunction in sepsis [17–19]. This has been sparsely in-
vestigated in intensive care.
The aim of this study was to test whether MR-proADM
and CT-proET-1 are associated with myocardial injury,
measured using transthoracic echocardiography and
hsTNT in patients with septic shock. We were also in-
terested in the dynamics of MR-proADM, CT-proET-1,
and hsTNT throughout the ICU stay, and how early
measurements (day 1) were related to early mortality
(day 7) and later mortality (day 28). Further, we assessed
whether a positive biomarker panel, consisting of MR-
proADM, CT-proET-1, and hsTNT changes the odds of
mortality.
Methods
The study was approved by the Regional Ethical Review
Board, Lund, Sweden (Dnr.187/2005). Informed consent
was sought either from the patient or, if not possible,
from the patient’s next of kin. The study design com-
prised a single-center, prospective observational cohort
of critically ill patients admitted to the mixed-bed ICU
of Skåne University Hospital, Malmö, Sweden. Data col-
lection lasted up to a maximum of 7 days, or until ICU
discharge, or death if either occurred before 7 days. Early
(7-day) and later (28-day) mortality was measured. Fifty-
five consecutive patients with septic shock were included
between year 2005 and 2007. Septic shock was defined
according to the criteria published by Dellinger et al.
[20]. Exclusion criteria were pregnancy, inherited abnor-
malities of coagulation, fibrinolytic therapy, compro-
mised immunity or a “Do not attempt resuscitation”
order. Patients could be included only once. All patients
were initially treated according to international guide-
lines for the management of sepsis and septic shock
[21]. After the initial resuscitation period, fluids were
given at the treating clinician’s discretion. Acute physiology
and chronic health evaluation (APACHE) II scores were
calculated at admission and sequential organ failure assess-
ment (SOFA) scores were calculated daily.
Biochemical analyses
Blood samples were collected from an indwelling arterial
line. MR-proADM and CT-proET-1 were measured four
times on day 1 (first sample within 6 hours of arrival to
the ICU), twice on day 2, and thereafter once daily until
ICU discharge, death or end of study. HsTNT was mea-
sured twice on day 1 (first sample within 12 hours of ar-
rival to the ICU) and thereafter once daily until ICU
discharge, death or end of study. The daily values of all
biomarkers were averaged to give a single representative
value for that day. The blood samples were sent to the
local clinical chemistry laboratory, Skåne University
Hospital, Malmö, Sweden, where they were centrifuged,
frozen at −80 °C, and stored.
MR-proADM and CT-proET-1 were batch-analyzed
using a sandwich immunoassay (BRAHMS GmbH/Ther-
moFischer Scientific, Henningsdorf, Germany). In the gen-
eral population, 90 % of measurements of MR-proADM
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are below 0.55 nmol/L [22] and the 99th percentile of CT-
proET-1 in a healthy population is 72.9 pmol/L [9]. The
analytical detection limits of MR-proADM and CT-proET-
1 were 0.08 nmol/L and 4.3 pmol/L. HsTNT was measured
using an immunoassay (Cobas e601, Roche Diagnostics
GmbH, Penzberg, Germany) [23]. The measurement range
is 3–10,000 ng/L and the upper reference limit (99th
percentile) is 14 ng/L in healthy volunteers.
Echocardiography
TTE examinations were performed within 12 hours of
inclusion for the evaluation of left ventricular (LV) systolic
function. Images were acquired using a Hewlett- Packard
Sonos 5500 (Andover, MA, USA) scanner and a 3 MHz
transducer. Two-dimensional (2D) imaging examinations
were performed in the standard apical four-chamber and
two-chamber views. Tissue harmonic imaging was used to
enhance 2D image quality. Parameters of LV systolic func-
tion (left ventricular ejection fraction (LVEF), mitral annu-
lar plane systolic excursion (MAPSE), peak systolic tissue
Doppler velocity imaging (TDIs) and velocity time integral
in the left ventricular outflow tract (LVOT VTI)) were ac-
quired as described previously [24].
Myocardial injury
Myocardial injury was defined as an hsTNT value ≥15 ng
on day 1 and at least two of the following echocar-
diographic parameters on day 1: LVEF ≤50 %, MAPSE
≤12 mm, or TDIs ≤7.5 cm/sec.
Statistics
A sample size of 46 patients was required to detect a
posttest myocardial injury risk of 0.75, assuming a base-
line risk of 0.3. This was calculated as a test of propor-
tions with a two-tailed α value of 0.05 and β of 0.8, with
a continuity correction applied. As we expected drop-
outs we arbitrarily chose to increase the sample size to a
convenience sample of 55 patients.
Data are presented as median (interquartile range), per-
centages or absolute values. IBM SPSS Statistics version
22 was used for statistical calculations. For non-normally
distributed variables we used non-parametric tests. Miss-
ing values were considered as randomly missing and were
not adjusted for. Spearman’s rank correlation was calcu-
lated to test correlation between two variables, and for dif-
ferences between two groups we used the Mann-Whitney
U test. Categorical data were analyzed with Fisher’s exact
test. We used Holm’s procedure to adjust for multiple
testing. Receiver operating characteristic (ROC) curve
analysis was performed with calculation of maximal area
under the curve (AUC). Youden’s index was used to define
optimal cutoff values. The positive predictive value (PPV)
and negative predictive value (NVP) were calculated.
For the evaluation of the diagnostic accuracy of each
biomarker, we calculated the positive likelihood ratio (LR+)
and negative likelihood ratio (LR-), where LR+ is the
sensitivity/(1 – specificity) and LR- is (1 – sensitivity)/
specificity. Confidence intervals (CI) were calculated
for each likelihood ratio. The pretest odds of mortality
is given by P/(1 – P), where P is the probability of the
mortality in the current study cohort. The posttest
odds, given a positive test, are the product of the LR+
and pretest odds, whereas the posttest odds, given a
negative test, are the product of the LR- and the pre-
test odds.
Results
Two patients were excluded due to lack of written con-
sent leaving 53 patients included in the study. Three pa-
tients had missing hsTNT and six patients had missing
echocardiographic data. The patients’ medical histories
divided them into surgical (n = 16) and medical (n = 37)
cases. The 7-day and 28-day mortality was 19 % and
28 %, respectively. Survivors tended to be younger, and
had lower APACHE II and SOFA scores at admission as
shown in Table 1.
Temporal development of biomarkers
Figure 1 (a-c) shows the temporal development of
MR-proADM, CT-proET-1, and hsTNT according to
short (7-day) and longer-term (28-day) mortality. Non-
Table 1 Baseline characteristics of all patients and according to survival
Mortality at 28 days Mortality at 7 days
All Survivors Non-survivors P value Survivors Non-survivors P value
(n = 53) (n = 38) (n = 15) (n = 43) (n = 10)
Age, years 65 (20) 60 (22) 72 (8) 0.007 61 (19) 76 (8) 0.026
APACHE II, score 24 (10) 23 (11) 28 (14) 0.026 24 (11) 29 (10) 0.015
SOFA score, admission 12 (5) 11 (4) 14 (2) 0.002 11 (4) 14 (3) 0.002
Body mass index, kg/m2 26 (5) 27 (7) 24 (4) 0.008 26 (7) 24 (4) 0.094
Gender (male/female), n 37/16 26/12 11/4 1 30/13 7/3 1
Medical/surgical, n 37/16 26/12 11/4 1 30/13 7/3 1
APACHE acute physiology and chronic health evaluation, SOFA sequential organ failure assessment
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Fig. 1 Temporal development of MR-proADM, CT-proET-1 and hsTNT
Lundberg et al. Critical Care  (2016) 20:178 Page 4 of 11
survivors generally had higher values of all biomarkers over
the 7-day period.
Relationship between MR-proADM, CT-proET-1,
and myocardial injury
There was statistically significant inverse correlation
between MR-proADM measured on day 1 and two of
the four echocardiographic markers of LV systolic dys-
function, MAPSE and LVOT VTI. Day 1 CT-proET-1
concentrations were inversely correlated to all LV systolic
function parameters (ρ = –0.43 to –0.48, p = 0.001–0.003).
Both MR-proADM and CT-proET-1 were also correlated
with hsTNT (ρ = 0.38, p = 0.007 and ρ = 0.40, p = 0.004, re-
spectively). Both biomarkers were significantly correlated
with each other (ρ = 0.68, p ≤ 0.001), age, and creatinine
(see Table 2).
Twenty-six patients had myocardial injury defined as
above, and these patients had significantly higher levels of
MR-proADM and CT-proET-1 (p = 0.007 and p < 0.001,
respectively) (see Table 3).
Relationship between biomarker concentrations on day 1
and mortality
The day-1 mean plasma levels according to 7-day and 28-
day mortality are displayed in Table 3. MR-proADM, CT-
proET-1 and hsTNT were significantly higher among
patients who did not survive 28 days. MR-proADM and
hsTNT but not CT-proET-1 were higher in patients who
did not survive 7 days.
Odds and predictive values for single and combined
biomarkers
Table 4 shows the AUC and cutoff values from the ROC
curves, and the corresponding PPVs and NVPs. The cut-
off values were used when calculating the LR and odds
shown in Table 5. The LR+ for MR-proADM was 4.3
when calculated for 7-day mortality. When MR-proADM
and CT-proET-1 were combined the LR+ increased. The
highest values for the LR+ were obtained when combining
all three biomarkers – the difference between the pretest
and posttest odds was up to 20-fold (0.35–6.97) for 28-day
mortality and 13-fold (0.19–2.49) for 7-day mortality.
When MR-proADM and CT-proET-1 were combined the
difference between the pretest and posttest odds was
12-fold (1.24–14.9) for myocardial injury.
Discussion
Biomarkers and myocardial injury
In this exploratory study we demonstrated significant rela-
tionships between MR-proADM/CT-proET-1 and myo-
cardial injury. The relationship was strongest and most
consistent with CT-proET-1. This finding supports a bio-
logically plausible relationship as both pro-hormones are
strongly vasoactive and may play key roles in sepsis-
associated myocardial injury. Indeed, we demonstrated
significant associations between both pro-hormones and
hsTNT and echocardiographic markers of LV systolic
dysfunction.
In epidemiological studies, increased MR-proADM
has been associated with poor cardiovascular outcomes
[22, 25, 26]. In sepsis there is upregulation of ADM ex-
pression [27, 28] and ADM seems to be important for
the initiation and continuation of hyperdynamic shock
in animal models [4, 5, 29–31]. Importantly, the adminis-
tration of anti-ADM antibodies prevents the hyperdynamic
response [27] and seems beneficial to survival [32, 33],
while exogenous ADM prevents and reverses hypodynamic
circulation and pulmonary hypertension, and reduces
endothelial hyperpermeability in experimental models
of septic shock [4, 5, 30, 34], suggesting possibilities for
therapeutic intervention. In this study we found only
moderate correlation between MR-proADM and two of
four echocardiographic markers of reduced LV systolic
function. Despite this there was strongly significant cor-
relation between proADM and hsTNT concentrations,
which could suggest a role of this pro-hormone in car-
diac injury.
Experimental and clinical studies link increased ET-1
levels to decreased cardiac performance [17, 19, 35–38].
This is supported by our findings of highly significant
correlation between CT-proET-1 levels and all echocar-
diographic markers of reduced LV systolic function, and
hsTNT. The results of these studies appear paradoxical
to earlier experimental data showing positive inotropic
effects of ET-1 [39, 40]. Thus, the role of ET-1 is still
Table 2 Correlation between MR-proADM/CT-proET-1 and echocardiographic markers of left ventricular systolic function, hsTNT,
age, and creatinine
LVEF MAPSE TDIs LVOT VTI hsTNT Age Creatinine
MR-proADM Correlation coefficient ρ -0.139 -0.320 -0.142 -0.310 0.376 0.342 0.741
p value 0.351 0.029 0.342 0.036 0.007* 0.012 >0.001*
CT-proET-1 Correlation coefficient ρ -0.439 -0.479 -0.430 -0.437 0.396 0.385 0.524
p value 0.002* 0.001* 0.003* 0.002* 0.004* 0.004* >0.001*
MR-proADM mid-regional pro-adrenomedullin, CT-proET-1 C-terminal pro-endothelin-1, LVEF left ventricular ejection fraction, MAPSE mitral annular plane systolic
excursion, TDIs peak systolic tissue Doppler velocity imaging, LVOT VTI velocity time integral in the left ventricle outflow tract, hsTNT high-sensitivity troponin T.
*P value lower than adjusted alpha after Holm’s procedure for multiple testing
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unclear and seems related to the balance between recep-
tor types.
Antagonism of endothelin pathways has been explored
in a number of experimental settings, and its effects dur-
ing septic shock are areas worth exploring [35–37, 41–43].
To our knowledge, there is only one other study investi-
gating the relationship between cardiac function and CT-
proET-1 in patients with septic shock. Furian et al. [17]
demonstrated significant association between CT-proET-1
and echocardiographic markers of left and right ven-
tricular dysfunction, but did not describe biochemical
markers of myocardial injury. Our findings highlight
the importance of CT-proET-1 in cardiac dysfunction
measured using echocardiography and cardiac troponins,
and in mortality. Importantly, the LR- of 0.25 indicates
that CT-proET-1 is useful for ruling out myocardial injury.
Taken together, our results indicate that the combination
of MR-proADM and CT-proET-1 might be a useful sup-
plement for the diagnosis of myocardial injury, as shown
by a LR+ of 12.
Biomarkers and mortality
We have shown that increased concentrations of MR-
proADM, CT-proET-1, and hsTNT are increased in
non-survivors of septic shock, supporting the results of
earlier studies [7, 11, 16, 19, 44–46]. MR-proADM and
hsTNT seem to be more important determinants of both
short-term and longer-term outcome, whereas CT-proET-
1 seems to be most significant for longer-term mortality
with higher concentrations detected in non-survivors on
days 2–5 (Fig. 1b). When considered as a pair, CT-proET-
1 and MR-proADM increased the odds for mortality
twofold to fivefold. When a combined panel of all three
biomarkers were positive, the posttest odds for mortality
increased 13-fold to 20-fold.
ProADM and proET-1 are especially attractive bio-
markers in septic shock because they are both endo-
thelium-derived pro-hormones and their end products
have important vasoregulatory opposing effects. As sug-
gested by Scheutz and colleagues [45] it is plausible
that the net balance between the hormones is of signifi-
cance for clinical outcome. Increased concentrations of
ADM and ET-1 have been described in patients with
systemic inflammatory response syndrome (SIRS) [47]
and septic shock [6, 7, 17, 29, 44–46, 48], and appear to
be related to severity and mortality, but dynamic evalua-
tions and their significance for short-term and long-term
mortality in patients with shock are poorly investigated.
Herein we demonstrated that concentrations of both pro-
hormones are higher in non-survivors, particularly during
the first 3 days of ICU admission (see Fig. 1).
In line with our results, Guignant et al. reported higher
initial levels of proADM among non-survivors of septic
shock. Further, the combination of proADM with a vaso-
constrictor biomarker, pro-vasopressin, was better for pre-
diction of 28-day mortality when assessed at day 1–2 than
the SOFA score and simplified acute physiology score
(SAPS) II [7]. Similarly, in a cohort of critically ill patients
with sepsis, Christ-Crain et al. found a significantly higher
level of proADM among intensive care unit (ICU) non-
survivors [46]. They reported an optimal cutoff value of
3.9 nmol/L for MR-proADM, resembling the optimal
cutoff of 3.5 nmol/L identified in this study for 28-day
mortality. The optimal cutoff identified by Guignant
et al. was also in this range (5 nmol/L) [7]. Taken to-
gether, these findings support proADM as a useful pre-
dictor of mortality.
Our results for ET-1 are different to those reported
previously, where no differences between survivors and
non-survivors were shown [45, 49]. There may be several
explanations for this. First, our patients were severely ill
with higher illness severity scores than in previous studies.
The median day 1 SOFA and APACHE II scores were 12
and 24, respectively, and all 53 patients were in shock
despite fluid resuscitation. Second, we used 7-day and
28-day mortality as outcome parameters, in contrast to
in-hospital mortality as used in some of the other studies.
Third, we collected blood 6-hourly in the first 24 hours,
and used average daily values in an attempt to capture
average values for each patient every day. In comparison,
Scheutz et al. collected a single sample within 24 hours of
ICU admission. Guignant et al. collected a single sample
within 48 hours of ICU admission and had a substantial
number of missing values. These reflect difficulties in the
conduct of clinical studies but may be of significance, as
measuring biomarker levels at an early stage, i.e., when the
Table 3 Biomarkers related to myocardial injury and mortality
Myocardial injury Mortality at 28 days Mortality at 7 days
No (n = 21) Yes (n = 26) P value Survivors Non-survivors P value Survivors Non-survivors P value
MR-proADM 2.5 (2.4) 5.2 (5.8) 0.007 3.0 (3.4) 6.3 (6.7) 0.010 3.3 (2.9) 7.1 (5.2) 0.002*
CT-proET-1 153 (111) 324 (238) <0.001* 188 (183) 289 (247) 0.027 198 (172) 332 (319) 0.088
hsTNT - - - 51 (85) 143 (444) 0.007 57 (126) 146 (388) 0.033
Creatinine - - - 138 (150) 182 (131) 0.211 122 (129) 200 (132) 0.048
MR-proADM mid-regional pro-adrenomedullin, CT-proET-1 C-terminal pro-endothelin-1, hsTNT high-sensitivity troponin T. *P value lower than adjusted alpha after
Holm’s procedure for multiple testing
Lundberg et al. Critical Care  (2016) 20:178 Page 6 of 11
Table 4 Area under the curve (AUC), cutoff and positive predictive value/negative predictive value (PPV/NPV)
Myocardial injury Mortality at 28 days Mortality at 7 days
Cutoff AUC Sensitivity Specificity PPV/NPV Cutoff AUC Sensitivity Specificity PPV/NPV Cutoff AUC Sensitivity Specificity PPV/NPV
MR-proADM 4.6 nmol/L 0.729 0.577 0.810 0.79/0.61 3.5 nmol/L 0.730 0.8 0.605 0.44/0.88 5.5 nmol/L 0.823 0.9 0.791 0.5/0.97
CT-proET-1 209 pmol/L 0.855 0.808 0.810 0.81/0.76 206 pmol/L 0.696 0.8 0.579 0.41/0.88 269 pmol/L 0.674 0.7 0.651 0.32/0.90
hsTNT - - - - - 114 ng/L 0.752 0.692 0.784 0.53/0.88 114 ng/L 0.74 0.75 0.738 0.35/0.94
APACHE II - - - - - 27 0.696 0.667 0.737 0.5/0.88 27 0.744 0.8 0.721 0.4/0.94









Table 5 Likelihood ratios (LR) (95 % CI) and odds



















MR-proADM 3.03 1.24/3.76 0.52 1.24/0.64 2.03 0.39/0.79 0.33 0.39/0.13 4.3 0.23/0.99 0.13 0.23/0.03
(1.18, 7.76) (0.32, 0.86) (1.269, 3.236) (0.116, 0.939) (2.32, 7.97) (0.02, 0.82)
CT-proET-1 3.39 1.24/4.20 0.25 1.24/0.31 1.79 0.39/0.70 0.46 0.39/0.14 2.01 0.23/0.46 0.46 0.23/0.11
(1.54, -7.46) (0.11, 0.57) (1.158, 2.762) (0.233, 0.987) (1.13, 3.57) (0.17, 1.22)
hsTNT - - - - 3.20 0.35/1.12 0.39 0.35/0.14 2.86 0.19/0.54 0.34 0.19/0.07




12 1.24/14.9 0.44 1.24/0.55 2.14 0.39/0.84 0.27 0.39/0.10 5.02 0.23/1.15 0.17 0.23/0.04




- - - - 19.92 0.35/6.97 NA* NA* 13.13 0.19/2.49 NA* NA*
(2.70, 146.88) (3.06,
56.24)
MR-proADM mid-regional pro-adrenomedullin, CT-proET-1 C-terminal pro-endothelin-1, hsTNT high-sensitivity troponin T. NA, not analyzed. *It was not possible to calculate the LR- for all three biomarkers combined,









patient is most unstable, may reveal important informa-
tion about the state of the cardiovascular system. It also
allows the possibility of early intervention and disease
staging.
Although elevated cTn is most commonly used for the
diagnosis of MI [50], increased cTns are commonly seen
in patients with septic shock without MI and are inde-
pendent predictors of mortality [11–15]. Recent studies
suggest that high-sensitivity assays may add to risk as-
sessment and prediction models [11, 16]. Our study con-
firms the importance of hsTNT for the outcome of
patients with septic shock. When used as an indicator of
injury along with echocardiographic parameters, it may
potentially be used to stratify risk and monitor treatment.
Both alone, but especially when used in a biomarker panel
with MR-proADM and CT-proET-1, hsTNT increased
the posttest odds ratio of mortality by 13-fold to 20-fold.
It remains to be seen whether this biomarker panel
ultimately improves current risk prediction models in
critical care. Another potential area of investigation is
the use of these biomarkers as a basis for selection of
patients for interventional studies, or as pharmacody-
namic markers for cardiac dysfunction.
Limitations
This paper has several limitations. This study was de-
signed to be exploratory in nature and the findings here
confirm associations between biomarkers and outcome,
and refrains from any conclusions on causality. The limited
number of outcome events does not allow adequate power
for multivariate analysis. As a rule-of-thumb 10 outcome
events would be required for each multivariate variable
[51], thus, future studies investigating the prognostic po-
tential of these biomarkers should be planned with this in
mind. While we realize the limitations of this type of
monocenter investigation, in particular the risk of overesti-
mation of effect size, we believe that our study contributes
new information to a hitherto under-investigated area.
Second, although we defined ICU admission as a starting
point for this study, patients have had variable times to
presentation, different degrees of shock and variable re-
sponses to fluid resuscitation, making the material poten-
tially heterogeneous. As dynamic changes in biomarker
levels may be important, particularly early in the course of
septic shock, we attempted to capture these changes by
measuring up to four times during the first 24 hours, and
twice daily during ensuing days. Closer sampling times
may have revealed different results. We have no data on
right ventricular echocardiographic parameters. As almost
all components of the endothelin system are upregulated
in pulmonary hypertension [8], and right ventricular dys-
function is common in septic shock, it is plausible that
high levels of CT-proET-1 could correlate with right ven-
tricular dysfunction. Because of the lack of a universal
definition of myocardial injury, our definition was arbitrary
but chosen on the basis of previous studies [23, 52–56]. As
premorbid echocardiographic data were not available,
we cannot exclude that some patients suffered from co-
existing myocardial dysfunction that was unrelated to
sepsis.
Conclusion
Our study shows that MR-proADM and CT-proET-1 are
associated with myocardial injury and dysfunction. It also
supports the concept of a composite biomarker panel for
adverse outcome prediction or risk stratification as pro-
posed in earlier studies in patients with sepsis. We found
that this particular combination of MR-proADM, CT-
proET-1 and hsTNT markedly increased the posttest odds
of death in a population of severely ill patients.
Key messages
 MR-proADM and CT-proET-1 are correlated with
myocardial injury in patients with septic shock
 A positive biomarker panel consisting of MR-
proADM, CT-proET-1, and hsTNT increases the
odds of both short-term and longer-term mortality
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